Marker Therapeutics (MRKR) Invested Capital (2016 - 2025)
Historic Invested Capital for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $18.4 million.
- Marker Therapeutics' Invested Capital rose 14684.49% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 14684.49%. This contributed to the annual value of $18.6 million for FY2024, which is 3206.44% up from last year.
- Per Marker Therapeutics' latest filing, its Invested Capital stood at $18.4 million for Q3 2025, which was up 14684.49% from $10.5 million recorded in Q2 2025.
- In the past 5 years, Marker Therapeutics' Invested Capital ranged from a high of $72.5 million in Q1 2021 and a low of $7.4 million during Q3 2024
- Its 5-year average for Invested Capital is $26.8 million, with a median of $18.6 million in 2024.
- Its Invested Capital has fluctuated over the past 5 years, first tumbled by 5543.2% in 2023, then soared by 14684.49% in 2025.
- Marker Therapeutics' Invested Capital (Quarter) stood at $44.0 million in 2021, then tumbled by 49.75% to $22.1 million in 2022, then crashed by 36.42% to $14.1 million in 2023, then soared by 32.06% to $18.6 million in 2024, then decreased by 0.91% to $18.4 million in 2025.
- Its Invested Capital stands at $18.4 million for Q3 2025, versus $10.5 million for Q2 2025 and $14.5 million for Q1 2025.